Literature DB >> 18067021

Complete molecular remission induced by concomitant cladribine--rituximab treatment in a case of multi-resistant hairy cell leukemia.

Francesco Forconi, Francesca Toraldo, Elisa Sozzi, Teresa Amato, Donatella Raspadori, Francesco Lauria.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18067021     DOI： 10.1080/10428190701647903

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  4 in total

1.  Achievement of complete remission of refractory hairy cell leukemia by rituximab progressing after allogeneic hematopoietic stem cell transplantation.

Authors:  Junichi Kiyasu; Motoaki Shiratsuchi; Rie Ohtsuka; Eriko Sada; Kensaku Idutsu; Eriko Nagasawa; Ryoichi Takayanagi; Yasunobu Abe
Journal:  Int J Hematol       Date:  2009-03-31       Impact factor: 2.490

2.  Bendamustine and rituximab in relapsed and refractory hairy cell leukemia.

Authors:  Mauricio Burotto; Maryalice Stetler-Stevenson; Evgeny Arons; Hong Zhou; Wyndham Wilson; Robert J Kreitman
Journal:  Clin Cancer Res       Date:  2013-10-04       Impact factor: 12.531

3.  Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia.

Authors:  Robert J Kreitman; Wyndham Wilson; Katherine R Calvo; Evgeny Arons; Laura Roth; Jeffrey Sapolsky; Hong Zhou; Mark Raffeld; Maryalice Stetler-Stevenson
Journal:  Clin Cancer Res       Date:  2013-11-25       Impact factor: 12.531

4.  Hairy cell leukemia: short review, today's recommendations and outlook.

Authors:  V Maevis; U Mey; G Schmidt-Wolf; I G H Schmidt-Wolf
Journal:  Blood Cancer J       Date:  2014-02-14       Impact factor: 11.037
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.